Zacks Research Has Negative Estimate for AXSM Q3 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for Axsome Therapeutics in a report released on Thursday, January 16th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.04 per share for the quarter, down from their previous forecast of $0.11. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.61) per share.

Other analysts have also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada upped their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 target price on shares of Axsome Therapeutics in a report on Thursday, December 12th. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, HC Wainwright reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Tuesday, December 31st. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.69.

Axsome Therapeutics Trading Down 1.9 %

Shares of Axsome Therapeutics stock opened at $91.93 on Monday. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $105.00. The firm has a market capitalization of $4.45 billion, a PE ratio of -14.08 and a beta of 1.04. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The company’s fifty day moving average price is $92.27 and its two-hundred day moving average price is $89.53.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter last year, the firm earned ($1.32) EPS.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of AXSM. Iron Triangle Partners LP acquired a new stake in shares of Axsome Therapeutics in the third quarter valued at approximately $22,671,000. Tri Locum Partners LP boosted its position in Axsome Therapeutics by 198.4% in the 2nd quarter. Tri Locum Partners LP now owns 306,513 shares of the company’s stock valued at $24,674,000 after buying an additional 203,802 shares during the last quarter. FMR LLC increased its stake in shares of Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after buying an additional 185,951 shares during the period. Franklin Resources Inc. raised its position in shares of Axsome Therapeutics by 47.5% during the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock worth $13,713,000 after acquiring an additional 51,696 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Axsome Therapeutics by 279.6% during the third quarter. Barclays PLC now owns 61,785 shares of the company’s stock valued at $5,552,000 after acquiring an additional 45,509 shares during the period. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.